Middle East conflict cost escalations
Prolonged Middle East tensions may increase costs for sourcing, logistics, and working capital, with limited ability to pass through.
medium · analyst_questionPiramal Pharma Ltd — Q4 FY26
Piramal Pharma reported a transitional FY26 with revenue decline due to inventory destocking in a key on-patent commercial product, subdued biotech funding in H1, and intensifie...
neutral
medium
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Tariff impact on CDMO business
US tariffs on Indian pharma could affect innovation-related work; management noted multiple mitigation paths but uncertainty remains.
medium · analyst_questionIntangible asset write-offs
A ₹176 crore impairment was taken on R&D intangibles due to changed market conditions; similar write-offs may recur.
low · data_observationRevenue lumpiness from CDMO
CDMO revenue remains H2-weighted, causing quarterly volatility; this pattern is expected to persist in FY27.
low · management_commentary